AI Engines For more Details: Perplexity Kagi Labs You
Venous Health: Diosmin is commonly used in the treatment of venous disorders, such as chronic venous insufficiency (CVI) and hemorrhoids. It works by improving venous tone and reducing venous congestion, thereby alleviating symptoms such as leg pain, swelling, and discomfort. Diosmin may also help to strengthen blood vessel walls and improve microcirculation, promoting better venous function and reducing the risk of complications associated with venous insufficiency.
Vascular Protection: Diosmin has been shown to have protective effects on the vascular system. It helps to reduce inflammation and oxidative stress in blood vessels, which can help to prevent or slow the progression of vascular diseases such as atherosclerosis (hardening of the arteries) and thrombosis (blood clot formation). Diosmin may also help to improve endothelial function and vascular tone, contributing to overall cardiovascular health.
Anti-inflammatory Effects: Diosmin exhibits anti-inflammatory properties, meaning it can reduce inflammation in the body. Chronic inflammation is associated with the development and progression of various diseases, including cardiovascular disease, neurodegenerative diseases, and cancer. By reducing inflammation, diosmin may help to alleviate symptoms and slow the progression of these diseases.
Antioxidant Effects: Diosmin acts as an antioxidant, meaning it can neutralize harmful free radicals in the body. Free radicals are unstable molecules that can damage cells and contribute to aging and various diseases. By scavenging free radicals, diosmin helps to protect cells from oxidative stress and reduce the risk of oxidative damage to tissues throughout the body.
Lymphatic Health: Diosmin may also have benefits for lymphatic health. It helps to improve lymphatic drainage and reduce lymphatic congestion, which can help to alleviate symptoms such as swelling and discomfort associated with lymphedema (accumulation of lymph fluid). Diosmin may also help to improve immune function and reduce the risk of infections by supporting lymphatic circulation and drainage.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Increases |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.2 | -0.2 | |
| ADHD | 1.3 | 0.1 | 12 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.9 | 0.8 | 0.13 |
| Allergies | 2.4 | 0.4 | 5 |
| Allergy to milk products | 0.2 | 0.2 | 0 |
| Alopecia (Hair Loss) | 0.8 | 0.8 | |
| Alzheimer's disease | 0.9 | 2.8 | -2.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.5 | 0.2 |
| Ankylosing spondylitis | 1.4 | 0.9 | 0.56 |
| Anorexia Nervosa | 0.9 | -0.9 | |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 0.9 | 0.5 | 0.8 |
| Atherosclerosis | 0.7 | 0.4 | 0.75 |
| Atrial fibrillation | 1.2 | 0.5 | 1.4 |
| Autism | 4.2 | 2.8 | 0.5 |
| Barrett esophagus cancer | 0.2 | 0.1 | 1 |
| Biofilm | 0.9 | 0.9 | |
| Bipolar Disorder | 0.2 | 0.6 | -2 |
| Brain Trauma | 0.4 | 0.5 | -0.25 |
| Cancer (General) | 0.1 | 1.9 | -18 |
| Carcinoma | 1.4 | 1.2 | 0.17 |
| Celiac Disease | 0.8 | 1.5 | -0.88 |
| Cerebral Palsy | 0.5 | 1.2 | -1.4 |
| Chronic Fatigue Syndrome | 3.1 | 1.9 | 0.63 |
| Chronic Kidney Disease | 1.6 | 0.6 | 1.67 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | 0.3 | 0.67 |
| Chronic Urticaria (Hives) | 0.5 | 0.1 | 4 |
| Coagulation / Micro clot triggering bacteria | 0.1 | 0.8 | -7 |
| Colorectal Cancer | 0.7 | 0.4 | 0.75 |
| Constipation | 0.2 | 0.7 | -2.5 |
| Coronary artery disease | 0.9 | 0.7 | 0.29 |
| COVID-19 | 4.6 | 4.5 | 0.02 |
| Crohn's Disease | 2.8 | 1.8 | 0.56 |
| cystic fibrosis | 0.6 | -0.6 | |
| deep vein thrombosis | 0.4 | -0.4 | |
| Depression | 4.8 | 3.4 | 0.41 |
| Dermatomyositis | 0.1 | 0.2 | -1 |
| Eczema | 0.9 | 0.3 | 2 |
| Endometriosis | 0.9 | 0.3 | 2 |
| Eosinophilic Esophagitis | 0.2 | -0.2 | |
| Epilepsy | 1.6 | 1 | 0.6 |
| Fibromyalgia | 1 | 0.5 | 1 |
| Functional constipation / chronic idiopathic constipation | 0.8 | 2 | -1.5 |
| gallstone disease (gsd) | 0.7 | 0.5 | 0.4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 1 | -4 |
| Generalized anxiety disorder | 1.1 | 0.7 | 0.57 |
| Glioblastoma | 0.1 | -0.1 | |
| Graves' disease | 0.6 | 1.1 | -0.83 |
| Halitosis | 0.4 | 0.1 | 3 |
| Hashimoto's thyroiditis | 1.8 | 0.6 | 2 |
| Hidradenitis Suppurativa | 0.1 | 0.2 | -1 |
| High Histamine/low DAO | 0.3 | 0.2 | 0.5 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 0.5 | 0.9 | -0.8 |
| Hyperlipidemia (High Blood Fats) | 0.4 | 0.5 | -0.25 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 0.9 | 2.8 | -2.11 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 0.2 | 0.3 | -0.5 |
| IgA nephropathy (IgAN) | 1.2 | -1.2 | |
| Inflammatory Bowel Disease | 2.2 | 2.1 | 0.05 |
| Insomnia | 0.7 | 0.5 | 0.4 |
| Intelligence | 0.1 | -0.1 | |
| Intracranial aneurysms | 0.6 | 0.3 | 1 |
| Irritable Bowel Syndrome | 1.8 | 1.2 | 0.5 |
| Liver Cirrhosis | 1.8 | 1.3 | 0.38 |
| Long COVID | 3.5 | 3.9 | -0.11 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.8 | 0.5 | 0.6 |
| Mast Cell Issues / mastitis | 0.1 | 0.2 | -1 |
| ME/CFS with IBS | 0.5 | 1.4 | -1.8 |
| ME/CFS without IBS | 1.3 | 0.6 | 1.17 |
| Menopause | 0.8 | 0.8 | |
| Metabolic Syndrome | 4 | 3 | 0.33 |
| Mood Disorders | 5.5 | 3.8 | 0.45 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.7 | -1.33 |
| Multiple Sclerosis | 1.7 | 1.2 | 0.42 |
| Multiple system atrophy (MSA) | 0.8 | 1.1 | -0.38 |
| neuropathic pain | 0.3 | 0.9 | -2 |
| Neuropathy (all types) | 0.5 | 0.3 | 0.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 2.3 | -0.92 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 5.4 | 2.1 | 1.57 |
| obsessive-compulsive disorder | 1.8 | 2.4 | -0.33 |
| Osteoarthritis | 1.1 | 1.1 | |
| Osteoporosis | 0.7 | 0.6 | 0.17 |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 2.3 | 2.9 | -0.26 |
| Polycystic ovary syndrome | 0.9 | 0.5 | 0.8 |
| Postural orthostatic tachycardia syndrome | 0.2 | -0.2 | |
| Premenstrual dysphoric disorder | 0.9 | 0.9 | |
| primary biliary cholangitis | 0.1 | 0.3 | -2 |
| Psoriasis | 1.8 | 0.9 | 1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3 | 1.5 | 1 |
| Rosacea | 0.8 | 0.3 | 1.67 |
| Schizophrenia | 1.8 | 1.1 | 0.64 |
| Sjögren syndrome | 1.4 | 1.1 | 0.27 |
| Sleep Apnea | 0.6 | 1 | -0.67 |
| Slow gastric motility / Gastroparesis | 0.4 | 0.2 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.4 | -3 |
| Stress / posttraumatic stress disorder | 1 | 1.4 | -0.4 |
| Systemic Lupus Erythematosus | 1.8 | 1 | 0.8 |
| Tic Disorder | 0.1 | 0.6 | -5 |
| Tourette syndrome | 0.4 | -0.4 | |
| Type 1 Diabetes | 1 | 0.7 | 0.43 |
| Type 2 Diabetes | 4 | 1.7 | 1.35 |
| Ulcerative colitis | 1.7 | 1 | 0.7 |
| Unhealthy Ageing | 2.8 | 0.5 | 4.6 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [44.222.131 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.131 ]
